Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Cedric_Francois
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
complement immunotherapy
|
| gptkbp:foundedYear |
2009
|
| gptkbp:hasCompany |
gptkb:Apellis_Pharmaceuticals,_Inc.
|
| gptkbp:headquartersLocation |
gptkb:Waltham,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ:APLS
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US03753U1060
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:Empaveli
gptkb:Syfovre |
| gptkbp:numberOfEmployees |
over 700 (2023)
|
| gptkbp:stockSymbol |
gptkb:APLS
|
| gptkbp:website |
https://apellis.com
|
| gptkbp:bfsParent |
gptkb:Apellis_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|